BEIJING, Feb. 28, 2026 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has entered into a strategic collaboration agreement with Youcare Pharmaceutical Group (悦康药业集团 or “Youcare”) (SH: 688658), a prominent integrated pharmaceutical enterprise in China. This partnership is designed to accelerate the digital transformation and improvement of chronic disease services through the application of artificial intelligence (“AI”).
Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance
The agreement signifies a shared commitment to implementing AI across various chronic care scenarios and enhancing full-lifecycle health management solutions. The two companies intend to establish a more accessible, efficient, and precision-focused healthcare service ecosystem, supporting China’s national strategy to digitalize and specialize chronic disease management.
As China’s system for chronic disease prevention and control enters a crucial phase of digital transformation, industry players are shifting from a drug-centric approach to a patient-centric healthcare model. In response, Fangzhou has developed its “AI + H2H (Hospital-to-Home)” smart healthcare ecosystem, integrating AI capabilities into consultation, medication management, and post-treatment follow-up services. Fangzhou has introduced a suite of AI-powered tools, including an AI physician assistant, AI medication assistant, AI health manager, and AI content-generation engine, aimed at boosting operational efficiency and enhancing the patient experience. Fangzhou plans to expand its AI deployment across all segments of the chronic disease management value chain in 2026.
The new partnership will focus on two main areas of collaboration:
- Joint Development of Digital Systems: Combining Youcare’s innovative pharmaceutical products and medical expertise with Fangzhou’s AI-driven service capabilities to create a digitally powered chronic disease management system.
- Expansion of Health Management Services: Exploring diverse collaboration models to broaden full-cycle health management in key therapeutic areas, such as cardiovascular, infectious diseases, and endocrine disorders, utilizing AI to increase patient access to high-quality medicines and professional care.
Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “This collaboration leverages our complementary strengths and represents a significant step toward building a new healthcare ecosystem.” He added that the company will continue to utilize its AI technologies, digital operations, and patient service capabilities to advance intelligent chronic care systems.
Yu Pengfei, Director and Deputy General Manager of Youcare, stated, “This partnership is a key move in expanding our focus beyond pharmaceutical supply to encompass comprehensive health services.” He noted that collaborating with Fangzhou’s AI-enabled chronic care platform could improve the accessibility and real-world impact of its innovative therapies.
Both companies indicated that the partnership, which integrates AI technology, chronic disease services, pharmaceutical innovation, and supply chain capabilities, aligns with China’s broader healthcare objectives, including the “Healthy China 2030” initiative.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company specializes in providing personalized medical care and AI-powered precision medicine solutions. For more information, visit .
About Youcare Pharmaceutical Group
Youcare Pharmaceutical Group (SH: 688658), recognized as one of “the top 100 enterprises of Chinese Pharmaceutical Industry,” was established in 2001. Headquartered in Beijing and listed in 2020 (Stock Code: 688658SH), it is a large-scale conglomerate engaged in new drug R&D, pharmaceutical manufacturing, distribution and sales, and international business.
Media Contact
For further inquiries or interviews, please contact:
Xingwei Zhao Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
